CRITERIUM, Inc.

DUBLIN--( BUSINESS WIRE )--The "ePRO, E-Patient Diaries and eCOA - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global ePRO, E-Patient Diaries and eCOA Market to Reach $4.7 Billion by 2030 The global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 14.7% over the analysis period 2022-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is projected to record a 14.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Epatient Reported Outcomes (epros) segment is estimated at 16.4% CAGR for the next 8-year period. The U.S. Market is Estimated at $561.4 Million, While China is Forecast to Grow at 17.5% CAGR The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$561.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$604.6 Million by the year 2030 trailing a CAGR of 17.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 14% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR. Key Attributes: Report Attribute Details No. of Pages 411 Forecast Period 2022 - 2030 Estimated Market Value (USD) in 2022 $1.6 Billion Forecasted Market Value (USD) by 2030 $4.7 Billion Compound Annual Growth Rate 14.4% Regions Covered Global MARKET OVERVIEW Pivotal Role of eCOA, ePRO and Patient Engagement in Transforming Patient Centricity An Introduction to ePRO, E-Patient Diaries and eCOA Pandemic Jolt Brings Strategic & Lasting Changes to Healthcare Sector COVID-19 Expedites Healthcare Ecosystem's Evolution for Better Care & Cost Savings Adoption of Telemedicine Services Accelerates Amidst the Pandemic Pandemic Impact on eCOA, ePRO Market COVID-19 Outbreak Compels Clinical Trials Industry to Move Towards ePRO eCOA Solutions Help Address Hurdles Due to COVID-19 Pandemic eCOA Playing a Part in Development of COVID-19 Vaccine Global Market Outlook eCOA: The Largest Category ePRO Offers Tremendous Opportunities in Improving Healthcare System Competition Competitive Market Presence - Strong/Active/Niche for Players Worldwide in 2023 (E) Recent Market Activity MARKET TRENDS & DRIVERS Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth Patient Engagement Practices of the Future to be Shaped by Trends of Increased Use of Personal Devices and Passive Data Key Patient Engagement Technology Trends and Innovations eCOA & ePRO: A Powerful Duo Serving Clinical Trials with Electronic Data Collection Rise in Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials Trends in Clinical Trials Space to Influence Market Demand Clinical Trials Increasingly Embraced Technology During COVID-19 Pandemic Shift towards Decentralized/Virtual Clinical Trials to Boost Market Prospects Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials Growing Volumes of Data Generation in Decentralized Trials: A Challenge Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market COVID-19 and Implications for Drug Development Regulations & Processes Rise in Telemedicine Services Present Market Opportunities Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems Moving over Paper Pains & Mastering the Art of Real-Time Data Collection with ePRO Delivering Better Data: A Key Benefit of ePRO Factors Ensuring Success of ePRO Implementations ePatient Reported Outcomes (PROs) Gain Importance in Oncology Studies Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems Integrating AI into ePRO Improves the Efficiency of ePRO Data Collection and Assessment Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth eCOA Grants The Best Route to Improve Data Quality & Patient Experience for Clinical Trials Benefits Offered by eCOA Systems over the Paper-Based Systems in Trials How to Successfully Implement eCOA Systems in Clinical Trials? New Technologies & Approaches with Potential to Augment Statistical Prowess of eCOA Technological Trends Transforming eCOA Solutions Market Future Trends in eCOA Market: A Review eCOA Proves Beneficial in Addressing Clinical Trial Challenges During COVID-19 Pandemic UAT, Challenges and Embedded UAT for eCOAs Benefits of BYOD for eCOAs E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market Major Benefits of ePatient Diary eCOA & ePRO to Help Mental Health Research Shed the Taboo Status & Move Forward Intriguing Perks of eCOA & ePRO for Mental Health Research Increase in Healthcare Spending to Propel Demand Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boost Market Challenges Facing Companies Implementing eCOA, ePRO & Patient-Centric Clinical Trials FOCUS ON SELECT PLAYERS (Total 85 Featured) Dassault Systemes SE (3DS) Almac Group Clinical Ink, Inc. Criterium, Inc. Dacima Software, Inc. Anju Software ArisGlobal LLC Cogstate Ltd. Cambridge Cognition Ltd. CliniOps Inc., Castor EDC ClinCapture Clinion Adelphi Group Crucial Data Solutions For more information about this report visit https://www.researchandmarkets.com/r/2dq4rn About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with Cancer Research UK, University College London, and the Francis Crick Institute to utilize our ultra-sensitive NeXT Personal® tumor-informed liquid biopsy assay for the TRACERx study, a groundbreaking lung cancer initiative, to identify and track minimal residual disease (MRD) potentially before recurrence is detected through standard of care technologies Presented new data to highlight NeXT Personal’s unparalleled sensitivity in four posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, including initial findings from research with University Medical Center Hamburg-Eppendorf (UKE), which showed that NeXT Personal may improve the ability to predict responses or resistance to immunotherapy earlier than imaging Extended partnership with AstraZeneca to use NeXT Personal to explore ultra-sensitive MRD measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development Partnered with Criterium and the Academic Breast Cancer Consortium (ABRCC) to conduct a prospective clinical trial to validate the clinical performance of the NeXT Personal assay to evaluate MRD and subsequent recurrence in patients with early-stage, resectable triple negative breast cancer (TNBC) Appointed Chris Hall as Chief Executive Officer (CEO) and a member of the Board, in addition to his role as President; promoted Aaron Tachibana to Chief Operating Officer (COO), in addition to his role as Chief Financial Officer (CFO); and promoted Richard Chen to Executive Vice President, Chief Medical Officer (CMO) and R&D “We grew revenue 24% in the first quarter relative to the first quarter of last year, demonstrating consistent execution against our sharpened strategic focus in both our clinical and biopharma businesses,” said Chris Hall, President and CEO of Personalis. “We are continuing to pursue revenue growth in three areas: winning in the MRD space, enabling customers to develop personalized cancer vaccines, and supporting biopharmaceutical customers with their clinical trials. This focus paves the way for us to enter into the clinical diagnostics market this year and become a critical partner in cancer recurrence monitoring and detection.” First Quarter Financial Highlights Reported total company revenue of $18.9 million for the first quarter of 2023, representing a 24% increase compared with $15.2 million for the first quarter of 2022. Revenue from pharma tests, enterprise, and other customers of $15.9 million in the first quarter of 2023, representing a 35% increase compared with $11.7 million in the first quarter of 2022; revenue from enterprise customers includes revenue from Natera of $9.5 million in the first quarter of 2023 Revenue from population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) of $3.0 million in the first quarter of 2023, compared with $3.5 million in the first quarter of 2022 Cash, cash equivalents, and short-term investments of $148.9 million as of March 31, 2023 Net loss of $28.7 million, and net loss per share of $0.61 based on a weighted-average basic and diluted share count of 46.7 million in the first quarter of 2023 Second Quarter and Full Year 2023 Outlook Personalis expects the following for the second quarter of 2023: Total company revenue of $16 million to $17 million Revenue from pharma tests, enterprise sales, and other customers of $13 million to $14 million Revenue from population sequencing of approximately $3 million Personalis expects the following for the full year of 2023: Total company revenue in the range of $68 million to $72 million Revenue from pharma tests, enterprise sales, and all other customers in the range of $59 million to $63 million Revenue from population sequencing of approximately $9 million Net loss of approximately $103 million, reduced from $113 million in 2022 due to realization of headcount reduction savings, partially offset by investments in clinical evidence generation and non-cash depreciation expense for the new facility Cash usage of approximately $75 million, reduced from $119 million in 2022 Webcast and Conference Call Information Personalis will host a conference call to discuss the first quarter financial results after market close on Wednesday, May 3, 2023 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar can be accessed at . A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and Twitter. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted and reported results should not be considered an indication of future performance. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “aim,” “continue to,” “expect,” “future,” “goal,” or “will” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements regarding NeXT Personal improving the ability to predict responses or resistance to immunotherapy earlier than imaging, the company entering into the clinical diagnostics market in 2023 and becoming a critical partner in cancer recurrence monitoring and detection, the company’s second quarter and full year financial guidance, cash runway, the company’s business outlook, and the company’s goals and aims. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Personalis’ actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers, including from Natera, which accounted for 50% of the company’s total revenue in the first quarter; the launch and market adoption of new products and new product features, such as NeXT Personal; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; whether orders for the NeXT Platform and revenue from biopharmaceutical customers and Natera increase or decrease in future periods; ability to demonstrate attributes or advantages of NeXT Personal or the Personalis NeXT Platform; the evolution of cancer therapies and market adoption of the company’s services; risks associated with COVID-19 or other health epidemics or pandemics; unstable market, economic and geo-political conditions, which may significantly impact the company’s business and operations and the business and operations of Personalis’ customers and suppliers; and legal proceedings to enforce patents, and the presumed validity or enforceability of the company’s patents or other intellectual property rights. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on February 23, 2023, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, being filed with the SEC later today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended March 31, 2023 2022 Revenue $ 18,860 $ 15,227 Costs and expenses Cost of revenue 14,130 10,949 Research and development 16,573 17,098 Selling, general and administrative 14,097 15,486 Restructuring and other charges 3,885 — Total costs and expenses 48,685 43,533 Loss from operations (29,825 ) (28,306 ) Interest income 1,253 144 Interest expense (47 ) (59 ) Other income (expense), net (26 ) 19 Loss before income taxes (28,645 ) (28,202 ) Provision for income taxes 14 7 Net loss $ (28,659 ) $ (28,209 ) Net loss per share, basic and diluted $ (0.61 ) $ (0.63 ) Weighted-average shares outstanding, basic and diluted 46,740,270 44,995,752 PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (unaudited) (in thousands) Three Months Ended March 31, 2023 2022 Pharma tests and services $ 6,333 $ 7,562 Enterprise sales 9,458 4,116 Population sequencing 3,005 3,501 Other 64 48 Total revenue $ 18,860 $ 15,227 PERSONALIS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) March 31, 2023 December 31, 2022 Assets Current assets Cash and cash equivalents $ 87,172 $ 89,128 Short-term investments 61,767 78,530 Accounts receivable, net 18,103 16,642 Inventory and other deferred costs 8,219 8,591 Prepaid expenses and other current assets 7,511 6,808 Total current assets 182,772 199,699 Property and equipment, net 61,446 61,935 Operating lease right-of-use assets 23,971 26,480 Other long-term assets 3,991 4,586 Total assets $ 272,180 $ 292,700 Liabilities and Stockholders’ Equity Current liabilities Accounts payable $ 10,927 $ 12,854 Accrued and other current liabilities 20,653 19,013 Contract liabilities 2,563 1,264 Total current liabilities 34,143 33,131 Long-term operating lease liabilities 40,309 41,041 Other long-term liabilities 4,096 389 Total liabilities 78,548 74,561 Commitments and contingencies Stockholders’ equity Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued — — Common stock, $0.0001 par value — 200,000,000 shares authorized; 46,774,490 and 46,707,084 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 5 5 Additional paid-in capital 583,151 579,456 Accumulated other comprehensive loss (455 ) (912 ) Accumulated deficit (389,069 ) (360,410 ) Total stockholders’ equity 193,632 218,139 Total liabilities and stockholders’ equity $ 272,180 $ 292,700 View source version on businesswire.com: Contacts Investor Relations Contact: Caroline Corner investors@personalis.com 415-202-5678 Media: pr@personalis.com Source: Personalis, Inc. View this news release online at:

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights. Recent Business Highlights Announced a continuing partnership with Moderna to provide genomic testing for their upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck Partnered with Criterium and the Academic Breast Cancer Consortium (ABRCC) to conduct a prospective clinical trial to validate the clinical performance of the NeXT Personal® assay to evaluate minimal residual disease (MRD) and subsequent recurrence in patients with early-stage, resectable triple negative breast cancer (TNBC) Initiated a research collaboration with University Medical Center Hamburg-Eppendorf (UKE) and its new Fleur-Hiege Center for Skin Cancer Research, where Dr. Klaus Pantel, Dr. Christoffer Gebhardt, and team are using NeXT Personal to track tumor response to immunotherapy (IO) in patients with melanoma, with the aim of gathering evidence to advance the use of ultra-sensitive MRD detection in routine clinical practice for IO therapy monitoring “We are excited to have completed our strategic review of the business, which has resulted in a new threefold focus on winning in MRD, leveraging our technology to power companies working on personalized cancer vaccines, and supporting pharmaceutical customers with clinical trials,” said Aaron Tachibana, Interim Chief Executive Officer and Chief Financial Officer. “Our partnership with Moderna using our NeXT Platform to provide genomic testing is an example of how we enable customers. With our sharpened focus in both our clinical and biopharma businesses, we believe we are well-positioned to advance the standard of care by transforming cancer recurrence detection and ongoing therapy monitoring.” Fourth Quarter Highlights Reported total company revenue of $16.7 million for the fourth quarter of 2022 and $65.0 million for the full year of 2022. Revenue from pharma tests, enterprise, and other customers of $15.8 million in the fourth quarter of 2022 compared with $15.4 million in the fourth quarter of 2021; revenue from enterprise customers includes revenue from Natera of $8.2 million in the fourth quarter of 2022 Revenue from population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) of $0.9 million in the fourth quarter of 2022, which is initial revenue from the new contract awarded in September 2022, compared with $5.3 million in the fourth quarter of 2021 Cash, cash equivalents, and short-term investments of $167.7 million as of December 31, 2022 Fourth Quarter and Full Year 2022 Financial Results Revenue of $16.7 million in the fourth quarter 2022; revenue of $65.0 million in the full year 2022 Net loss of $31.1 million, and net loss per share of $0.67 based on a weighted-average basic and diluted share count of 46.3 million in the fourth quarter 2022; net loss of $113.3 million, and net loss per share of $2.48 based on a weighted-average basic and diluted share count of 45.7 million in the full year 2022 First Quarter and Full Year 2023 Outlook Personalis expects the following for the first quarter of 2023: Total company revenue of approximately $17.5 million Revenue from pharma tests, enterprise sales, and other customers of approximately $14.5 million Revenue from population sequencing of approximately $3.0 million Personalis expects the following for the full year of 2023: Total company revenue in the range of $68 million to $72 million, based on its strategic review of accounts and pruning of unprofitable business Revenue from pharma tests, enterprise sales, and all other customers in the range of $59 million to $63 million Revenue from population sequencing of approximately $9.0 million Net loss of approximately $103 million, down from $113 million in 2022 due to realization of headcount reduction savings, partially offset by investments in clinical evidence generation and non-cash depreciation expense for the new facility Cash usage of approximately $75 million, down from $119 million in 2022 Webcast and Conference Call Information Personalis will host a conference call to discuss the fourth quarter and full year 2022 financial results after market close on Thursday, February 23, 2023 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar can be accessed at . A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Personalis, Inc. Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and News Center, and follow Personalis on LinkedIn and Twitter. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted and reported results should not be considered an indication of future performance. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “aim,” “continue to,” “expect,” “future,” “goal,” or “will” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements regarding the company’s first quarter and full year financial guidance, cash runway, the company’s business outlook, and the company’s goals and aims. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Personalis’ actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers, including from Natera, which accounted for an estimated 49% of the company’s total revenue in the fourth quarter and an estimated 41% for the full year of 2022; the launch and market adoption of new products and new product features, such as NeXT Personal; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; whether orders for the NeXT Platform and revenue from biopharmaceutical customers and Natera increase or decrease in future periods; ability to demonstrate attributes or advantages of NeXT Personal or the Personalis NeXT Platform; the evolution of cancer therapies and market adoption of the company’s services; risks associated with COVID-19 or other health epidemics or pandemics; unstable market, economic and geo-political conditions, which may significantly impact the company’s business and operations and the business and operations of Personalis’ customers and suppliers; and legal proceedings to enforce patents, and the presumed validity or enforceability of the company’s patents or other intellectual property rights. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission (SEC) on November 2, 2022, and its Annual Report on Form 10-K for the year ended December 31, 2022, being filed with the SEC later today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. PERSONALIS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 (unaudited) Revenue $ 16,722 $ 20,682 $ 65,047 $ 85,494 Costs and expenses Cost of revenue 14,410 12,686 51,697 53,837 Research and development 16,569 14,512 64,912 49,312 Selling, general and administrative 17,828 13,709 63,969 47,698 Total costs and expenses 48,807 40,907 180,578 150,847 Loss from operations (32,085 ) (20,225 ) (115,531 ) (65,353 ) Interest income 1,160 81 2,396 367 Interest expense (47 ) (59 ) (201 ) (184 ) Other income (expense), net (88 ) 1 61 (42 ) Loss before income taxes (31,060 ) (20,202 ) (113,275 ) (65,212 ) Provision for (benefit from) income taxes 8 (3 ) 40 14 Net loss $ (31,068 ) $ (20,199 ) $ (113,315 ) $ (65,226 ) Net loss per share, basic and diluted $ (0.67 ) $ (0.45 ) $ (2.48 ) $ (1.49 ) Weighted-average shares outstanding, basic and diluted 46,264,217 44,808,998 45,704,805 43,886,730 PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (in thousands) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 (unaudited) Pharma tests and services $ 7,400 $ 9,335 $ 29,552 $ 30,282 Enterprise sales 8,251 5,807 26,641 8,774 Population sequencing 887 5,304 8,443 45,671 Other 184 236 411 767 Total revenue $ 16,722 $ 20,682 $ 65,047 $ 85,494 PERSONALIS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) December 31, December 31, 2022 2021 Assets Current assets Cash and cash equivalents $ 89,128 $ 105,585 Short-term investments 78,530 181,479 Accounts receivable, net 16,642 18,468 Inventory and other deferred costs 8,591 5,610 Prepaid expenses and other current assets 6,808 7,089 Total current assets 199,699 318,231 Property and equipment, net 61,935 19,650 Operating lease right-of-use assets 26,480 53,822 Other long-term assets 4,586 4,825 Total assets $ 292,700 $ 396,528 Liabilities and Stockholders’ Equity Current liabilities Accounts payable $ 12,854 $ 9,221 Accrued and other current liabilities 19,013 18,110 Contract liabilities 1,264 3,982 Total current liabilities 33,131 31,313 Long-term operating lease liabilities 41,041 52,797 Other long-term liabilities 389 2,117 Total liabilities 74,561 86,227 Commitments and contingencies Stockholders’ equity Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued — — Common stock, $0.0001 par value — 200,000,000 shares authorized; 46,707,084 and 44,904,512 shares issued and outstanding at December 31, 2022 and 2021, respectively 5 4 Additional paid-in capital 579,456 557,558 Accumulated other comprehensive loss (912 ) (166 ) Accumulated deficit (360,410 ) (247,095 ) Total stockholders’ equity 218,139 310,301 Total liabilities and stockholders’ equity $ 292,700 $ 396,528